Bristol-Myers Squibb Compnay

Rex Denton

Jere E Meredith, Jr

John E Macor

Richard Eric Olson

Ivar M McDonald

Dalton King

Haiquan Fang

F Christopher Zusi

James H Cook, Ii

Christiana I Iwuagwu

Matthew D Hill

Robert A Mate

Nenghui Wang

Kimberley A Lentz

James H Ii Cook

The disclosure generally relates to compounds of the following formula, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs

The present invention relates to the biomarker TFF-3 that measures &#x3b3;-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by &#x3b3;-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage.

Method of generating a dosing schedule using gamma secretase notch biomarkers

Gamma secretase notch biomarkers

Growing community of inventors

Madison, CT, United States of America

Rex Denton